Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 07, 2015 12:12 AM ET


Company Overview of CROMA-PHARMA GmbH

Company Overview

CROMA-PHARMA GmbH develops, markets, and commercializes products in ophthalmology, osteoarthritis, and aesthetic dermatology fields. It offers eye drops and ointments for the treatment of dry eyes, medicinal products, intraocular lenses, viscoelastics, vitamac, vitreo-retinal products, and instruments and surgical devices. The company also provides food supplements for maintaining healthy joints and cartilages; coated tablets to support the body’s natural protection mechanisms against cartilage deterioration and preserve a healthy musculoskeletal system; biofermentativ produced hyaluronic acids to resemble the body’s own hyaluronic acid; and products for viscosupplementation therapy of large...

Industriezeile 6

Leobendorf,  2100


Founded in 1976


43 22 62 684 68 0


43 22 62 684 68 165

Key Executives for CROMA-PHARMA GmbH

Founder, President and Managing Director
Managing Director and Vice-President
Managing Director and Vice-President
Compensation as of Fiscal Year 2014.

CROMA-PHARMA GmbH Key Developments

Croma-Pharma Mulls IPO

Croma-Pharma Gmbh is considering an initial public offering (IPO) in 3-5 years, according to WirtschaftsBlatt which cited one of the owners, Andreas Prinz.

Croma-Pharma Gmbh Announces the Signing of Distribution Agreement with Hugel Inc

Croma-Pharma Gmbh announced the signing of a 10 year distribution agreement with Hugel Inc. CROMA-PHARMA will become the exclusive Distribution Partner and will be responsible for conducting the required clinical trials and studies. CROMA-PHARMA expects to invest an estimated two-digit million Euro amount for conducting these studies. Following the final approval of FDA, EMA and other authorities, CROMA-PHARMA will then market the new products in Europe, North America and Oceania markets. CROMA-PHARMA will promote the new products under their own brand. Products shall enter the markets in 2018. Forecast of sales until 2021 estimate returns of more than EUR 100 million in this dynamically growing market.

Similar Private Companies By Industry

Company Name Region
AlcaSynn Pharmaceuticals GmbH Europe
Actiopharm HandelsGmbH Europe
Biomay Produktions- und Handels AG Europe
Novartis Pharma GmbH (Austria) Europe
Covidien Austria GmbH Europe

Recent Private Companies Transactions

September 23, 2014
CROMA-PHARMA GmbH, Ophthalmology and Orthopaedics Divisions

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CROMA-PHARMA GmbH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at